GlassScriptPhysician profile
Kari K Hooper
NPI 1760681381
$1,006.28
in general payments reported to CMS, 2019-2025
26 companies · $180 in 2025
The $180 reported for 2025 was more than what 78% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.14 · 2020: $105 · 2022: $248 · 2023: $203 · 2024: $251 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $121.76 | 2020-2022 | |
| Blueprint Medicines Corporation | $109.46 | 2024 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $98.26 | 2022-2025 | Enhertu, Lynparza, Imfinzi |
| Regeneron Healthcare Solutions, INC. | $66.75 | 2022-2025 | Libtayo |
| Daiichi Sankyo INC. | $55.09 | 2022-2025 | Enhertu |
| Ipsen Biopharmaceuticals, INC | $54.98 | 2022-2025 | Onivyde |
| Novartis Pharmaceuticals Corporation | $54.65 | 2023-2024 | |
| Amgen INC. | $53.82 | 2022-2023 | Xgeva, Vectibix, Nplate |
| Adc Therapeutics America, INC. | $40.63 | 2022-2023 | |
| Eisai INC. | $39.49 | 2022-2023 | |
| Incyte Corporation | $34.18 | 2022-2024 | Monjuvi |
| Exelixis INC. | $30.91 | 2023 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.92 | 2023 | Gilotrif |
| Seagen INC. | $24.27 | 2023 | |
| Verity Pharmaceuticals INC. | $22.47 | 2023 | Trelstar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $19.14 | 2019 | |
| Caris Mpi, INC. | $18.28 | 2025 | Mi Cancer Seek |
| Roche Diagnostics Corporation | $17.60 | 2025 | Cobas 4800 Ct/Ng Test V2.0 |
| G1 Therapeutics, INC. | $17.45 | 2022 | |
| Pfizer INC. | $16.33 | 2024 | |
| Janssen Biotech, INC. | $15.32 | 2025 | Rybrevant |
| Taiho Oncology, INC. | $14.80 | 2022 | |
| Puma Biotechnology, INC. | $14.11 | 2024 | |
| Adaptive Biotechnologies Corporation | $14.00 | 2023 | Clonoseq |
| Glaxosmithkline, LLC. | $13.87 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Hooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.